Table 1

Patient demographics and baseline folic acid, B6, and B12 vitamin deficiency markers

StudyAge (no. of patients)
Gender (no. of patients)
BSAa (m2)mean, rangePS(no. of patients)
tHcy (μmol/liter)mean, rangeCyst (μmol/liter)mean, rangeMMA (nmol/liter)mean, range
<65≥65MaleFemale0–12
Phase I combination,b n = 79611851281.89, 1.27–2.477979.06, 3.6–27.4376, 98–2481206, 67–1065
Phase II
 Colorectal cancer, n = 35241122131.90, 1.45–2.2331411.7, 6–22.5224, 50–1303280, 68–2170
 Pancreas cancer, n = 41261523181.85, 1.22–2.6134712.8, 4.7–132.4235, 52–869341, 29–8507
 Esophageal and gastric  cancer, n = 231671761.69, 1.26–2.2221212.6, 6.3–31.9250, 87–718262, 96–1192
 Breast cancer, n = 464240461.77, 1.48–2.224249.0, 4.3–20.5396, 80–2234173, 79–734
 Cervical cancer, n = 981091.61, 1.25–1.97907.7, 5.4–10.5155, 89–282223, 78–482
 NSCLC cancer, n = 13941031.84, 1.30–2.161129.1, 3.7–15.4533, 198–1921179, 97–303
Total patients1866012312322422
Mean values1.84, 1.22–2.6110.3, 3.5–132.4309, 50–2481237, 29–8507
  • a BSA, body surface area; Cyst, cystathionine; NSCLC, non-small cell lung cancer.

  • b Patients with different primary tumor types.